MTOR and systemic lupus erythematosus: Importantly, SGLT2is or dapagliflozin block mTOR activation in macrophages as well as in podocytes.23 38 It is well established that mTOR plays a key role in adaptive immune system activation, proinflammatory lineage development39 and podocyte and endothelial cell dysfunction,40 which underscores the implication of mTOR blockade in patients with SLE.41 42 SGLT2is or dapagliflozin might act, at least partially via mTOR inhibition, as adjuvant immune modulatory treatments for SLE along with their renal/cardiac protective properties.